Monopar Therapeutics - 8-K Filing
Monopar initiates rolling NDA submission for ALXN1840 in Wilson disease (Items: 7.01 Regulation FD Disclosure On July 22, 2026, Monopar Therapeutics Inc, 9.01 Financial Statements and Exhibits)
Tickers: $MNPR
More Regulatory news
- Solana Co - 10-Q Filing
- Solana Co - 8-K Filing
- DeFi Development Corp. - 8-K Filing
- Stablecoin Development Corp - 8-K Filing
- BCP Investment Corp - 8-K Filing
- OneWater Marine Inc. - 8-K Filing
- Moleculin Biotech, Inc. - 8-K Filing
- Investcorp Credit Management BDC, Inc. - 8-K Filing
- Presurance Holdings, Inc. - 10-Q Filing
- Corteva, Inc. - 8-K Filing